FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma

Authors :: Fabio Piscaglia
Enrico Galmozzi
Francesca Benevento
Floriana Facchetti
Luca Faloppi
Stefano Cascinu
Annalisa De Silvestri
Mario Scartozzi
Andrea Casadei Gardini
Carmine Tinelli
Pietro Lampertico
Giorgia Marisi
Massimo Iavarone
Angelo Sangiovanni
Luca Ielasi
Source :: Journal of Hepatology. 70:e607
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
Sorafenib
medicine.medical_specialty
Hepatology
business.industry
medicine.disease
Internal medicine
Hepatocellular carcinoma
medicine
business
Adverse effect
Gene
Dose Modification
medicine.drug

Full Text Access

Tools